Please login to the form below
care
This page shows the latest care news and features for those working in and with pharma, biotech and healthcare.
In plain sight
I usually wouldn’t care about pop culture awards – this time is different. ... Or worse yet, have heard of it and don’t care about it.
Latest news
-
Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
Bamlanivimab-treated care home residents and staff had a significant reduction in COVID-19 risk. ... Currently, residents and staff in care homes have been identified as a top priority group to receive COVID-19 vaccines.
-
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
Care Excellence (NICE).
-
FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease
placebo. “Since its US approval, Esbriet has become a standard of care for people living with idiopathic pulmonary fibrosis,” said Levi Garraway, chief medical officer and head of Global Product Development,
-
UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains
In the final day 29 results, remdesivir plus standard-of-care treatment were able to cut the time to clinical recovery by five days compared to placebo, with a median time ... Another study, SIMPLE-Moderate, showed statistically improved clinical
-
Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
Strategy. The Department of Health and Social Care (DHSC) has announced that a total of 4.06 million people have received the first dose of a COVID-19 vaccine, as of ... That figure includes more than half of those aged 80 and over and more than half of
More from news
Approximately 42 fully matching, plus 2,738 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Amgen developed a portfolio of supportive cancer care drugs including Epogen, Neupogen and Aranesp, and Endo Pharmaceuticals developed a pipeline of pain products that includes Lidoderm, Percocet and Opana. ... Novartis created Novartis Oncology in 2016
-
The search for effective drug treatments for COVID-19
NIAID’s Adaptive COVID-19 Treatment Trial (ACTT-1) showed that remdesivir Standard of Care (SOC) significantly shortened time to recovery, provided greater clinical improvement and also reduced disease progression compared ... a 10-day dosing regimen
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care. ... Driving an evolution in care. There is a very real and unmet need to improve the standard of care for people with CKD.
-
Three ways AI will change healthcare in the next decade
AI-enabled solutions will also enhance patient engagement in their own care, giving them the knowledge that they need to take their health into their own hands. ... Streamlining the delivery of healthcare. The growing use of big data and AI will also
-
Putting theory into practice
Exploring the gap. To explore this gap, we decided to study the uptake of five different innovative medical technologies across multiple secondary care centres. ... This adoption process often takes place in a separate clinical sphere, such as when one
More from intelligence
Approximately 5 fully matching, plus 509 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations, Keytruda has become a blockbuster immunotherapy as well as introducing a new standard-of-care for
-
NICE looks internally for new chief executive
The National Institute for Health and Care Excellence (NICE) has appointed Gillian Leng (pictured above), CBE, as its new chief executive, who assumes the role from long-serving chief Sir Andrew ... Leng has been deputy chief executive at NICE since 2007
-
Four Health announces a pair of internal promotions
As a managing director, Springham will head up Four Health Media – the group's health care professionals media planning and buying specialists. ... In addition, Smith has an in-depth knowledge of the nursing and primary care market, after spending
-
Porterhouse announces members of medical advisory group
The group offers first-hand clinical experience to both colleagues and clients, adding value and insight into what resonates with health care professionals and patients.
-
New hires at Abbott, Kite and Arrakis Therapeutics
Starting off in Abbott’s Diabetes Care business, Ford has since served in many leadership roles within the company, including in the Nutrition and Medical Device businesses. ... Jude Medical – Abbott’s largest acquisition. He also led Abbott’s
More from appointments
Approximately 3 fully matching, plus 188 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
Non-urgent care has been paused, as doctors and nurses have been redeployed in the effort against the pandemic. ... For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover.
-
3 reasons why clinical trials will thrive in 2021
With reduced access to primary care, limited capacity in hospitals, and clinical trial participants unable to visit investigator sites, it’s taken countless innovative changes in procedures to enable hospitals, clinics,
-
2020 - a year to remember or forget?
HCPs had to adjust how they delivered care (often though telemedicine) and address the many wider needs such as access to medicines.
-
Porphyria Awareness Week – Round Up
We recognise that only true engagement can facilitate change and we use our combination of scientific, creative and technical expertise to stimulate optimal participation of all those in the care pathway. .
-
emotive supports Rare Disease Day 2019
On 20th February, we attended ‘The Unusual Suspects: Rare Diseases in Everyday Medical Care” at the Royal Society of Medicine, hosted by Medics 4 Rare Diseases (M4RD). . ... We recognise that only true engagement can facilitate change and we
More from PMHub
Approximately 34 fully matching, plus 547 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU
- Pfizer/BioNTech reach vaccine supply agreement with COVAX
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- An EU emergency health fund to limit the impact of future crises
- Mistrust in medical research: a patient perspective
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
